The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Vaccine Hesitancy: Wariness Is Rare, But There’s a Wider Worry About COVID Vaccines’ Efficacy in Some Populations

Vaccine Hesitancy: Wariness Is Rare, But There’s a Wider Worry About COVID Vaccines’ Efficacy in Some Populations

July 6, 2021 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

“Patients may balk since the vaccine may not be effective in them. Our data suggests this is an uncommon outcome, though. Around 85% had good responses. So again, we continue to preach getting vaccinated as the most frugal action,” he says.

You Might Also Like
  • Researchers Explore Response to COVID-19 Vaccines in the Elderly
  • More Info on the J&J COVID-19 Vaccine Thrombosis Scare
  • How Immunosuppression May Affect COVID-19 Vaccine Response
Explore This Issue
August 2021
Also By This Author
  • Adapting Care for Pediatric Patients & Parents During the Pandemic: Q&A with Sangeeta Sule, MD, PhD

Both Dr. Kim and Dr. Paik say current efforts to study the safety and immunogenicity of an additional booster of vaccine, including by the National Institutes of Health, are important. “Substantial work is being put into determining how to best protect those people whose original vaccine response was poor,” says Dr. Kim.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Benefits Greater than Risk

Dr. Prahalad says he is aware of emerging reports on suboptimal vaccine responses in adult patients, but he emphasizes the benefits of COVID-19 vaccination are greater than the risks to his young patients, especially the risk of hospitalization due to MIS-C.

“Generally, individuals who have been vaccinated tend to have milder disease if they are infected, which favors immunization over natural infection. Fortunately, the science is moving rapidly, and so if reports suggest that individuals on immunosuppression need booster doses, we will recommend that to ensure protection,” Dr. Prahalad says.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Stromquist says that once he explains how the vaccines work and their safety, his patients usually get a shot. He just tells them he is happy about their decision.

“It does not help to browbeat anyone, because some people may be worried and scared. I tell them that it is okay to feel worried and scared. I think validation is important,” Dr. Stromquist says.


Susan Bernstein is a freelance journalist based in Atlanta.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. U.S. Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation. Vaccine hesitancy for COVID-19: state, county and local estimates. 2021 May 28.
  2. Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: Version 2. Arthritis Rheumatol. 2021 Jun 15. Early view.
  3. Coronavirus (COVID-19) Update: FDA authorizes Pfizer/BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic. U.S. Food and Drug Administration. 2021 May 10.
  4. Boyarsky BJ, Ruddy JA, Connolly CM, et al. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021 Mar 23;annrheumdis-2021-220289.
  5. Deepak P, Kim W, Paley MA, et al. Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. medRxiv. 2021 Apr 9. Preprint.

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Conditions Tagged With: COVID-19, vaccination, vaccine, vaccine hesitancyIssue: August 2021

You Might Also Like:
  • Researchers Explore Response to COVID-19 Vaccines in the Elderly
  • More Info on the J&J COVID-19 Vaccine Thrombosis Scare
  • How Immunosuppression May Affect COVID-19 Vaccine Response
  • COVID-19 Vaccination Strategies Suggested for Patients on Anti-Rheumatic Immunosuppressive Therapy

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)